Once model verification assessments were completed and basal hormone and glucose responses determined, two SSTR2 antagonist compounds (PRL-2903 and ZT-01) were tested for hypoglycemia prevention in T2D rats and controls in two experiments. Here, SSTR2 is linked to type 2 diabetes mellitus.